文献速递心力衰竭与心肌病

连续KCCQ评分与射血分数保留和降低心衰患者死亡及住院的关联

Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究基于TOPCAT和HF-ACTION两项随机试验的二次分析,评估既往、当前及变化的KCCQ总分与心衰患者死亡和住院的关联。结果显示,在HFpEF和HFrEF患者中,最近的KCCQ评分与后续心血管死亡/心衰住院风险降低的关联最强,提示连续测量患者报告结局可用于更新预后评估。

要点

  • 最近一次KCCQ评分较既往评分或评分变化与后续心血管死亡/心衰住院的关联更强。
  • KCCQ评分每5分差异对应HFpEF和HFrEF患者后续风险降低约6%-10%。
  • 在心衰临床管理中连续测量KCCQ可提供更新的预后评估。

核心结论

  • 在心衰患者的连续健康状态评估中,最近的KCCQ评分与后续死亡和心血管住院的关联最强,且见于HFpEF和HFrEF。

研究设计与样本

  • TOPCAT试验二次分析纳入1372例HFpEF患者,HF-ACTION试验纳入1669例HFrEF患者;分析中 eligible 的TOPCAT参与者1767例、HF-ACTION参与者2130例。

主要发现

  • 在未调整分析中,既往或当前KCCQ-os每5分差异与HFpEF患者后续心血管死亡/首次心衰住院风险降低6%(95%CI 4%-8%)至9%(95%CI 7%-11%)相关(P<.001),与HFrEF患者风险降低6%(95%CI 4%-9%)至8%(95%CI 5%-10%)相关(P<.001)。
  • 同时纳入既往和当前KCCQ-os的模型中,仅当前KCCQ-os与HFpEF患者后续心血管死亡/首次心衰住院风险降低10%(95%CI 7%-12%)相关(P<.001),与HFrEF患者风险降低7%(95%CI 3%-11%)相关(P<.001)。
  • 当同时考虑当前KCCQ-os和ΔKCCQ-os、调整重要患者和治疗特征、纳入3次连续KCCQ-os评分以及以全因死亡为结局时,结果相似。

临床怎么用

  • 在心衰临床诊疗中连续测量KCCQ等患者报告结局,可提供更新的预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While there is increasing emphasis on incorporating patient-reported outcome measures in routine care for patients with heart failure (HF), how best to interpret longitudinally collected patient-reported outcome measures is unknown. OBJECTIVE: To examine the strength of association between prior, current, or a change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores with death and hospitalization in patients with HF with preserved (HFpEF) and reduced (HFrEF) ejection fractions. DESIGN, SETTING, AND PARTICIPANTS: Secondary analyses of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial of 1372 patients with HFpEF, conducted between August 2006 and January 2012, and the HF-ACTION trial that included 1669 patients with HFrEF, conducted between April 2003 and February 2007. EXPOSURES: Prior, current, and change in KCCQ Overall Summary scores (KCCQ-os) in 5-point increments (higher scores indicate better health status). MAIN OUTCOMES AND MEASURES: Time to cardiovascular death/first HF hospitalization (primary outcome) and all-cause death (secondary outcome). RESULTS: Of 1767 eligible TOPCAT participants, 882 were women (49.9%), and the mean (SD) age was 71.5 (9.7) years. Of 2130 eligible HF-ACTION participants, 599 were women (28.1%), and the mean age was 58.6 (12.7) years. Each 5-point difference in prior or current KCCQ-os scores was associated with a 6% (95% CI, 4%-8%; P < .001) to 9% (95% CI, 7%-11%; P < .001) lower risk for subsequent cardiovascular death/first HF hospitalization in patients with HFpEF and 6% (95% CI, 4%-9%; P < .001) to 8% (95% CI, 5%-10%; P < .001) lower risk for subsequent cardiovascular death/first HF hospitalization in patients with HRpEF and HFrEF in unadjusted analyses. Results were similar for change in KCCQ-os. In models with the prior and current KCCQ-os, only the current KCCQ-os was significantly associated with 10% (95% CI, 7%-12%; P < .001) and 7% (95% CI, 3%-11%; P < .001) lower risk for subsequent cardiovascular death/first HF hospitalization in patients with HFpEF and HFrEF, respectively. Similar results were observed when the current and Δ KCCQ-os were considered together, when adjusted for important patient and treatment characteristics, when including 3 sequential KCCQ-os scores, and when examining all-cause death as the outcome. CONCLUSIONS AND RELEVANCE: In serial health status evaluations of patients with HF, the most recent KCCQ score was most strongly associated with subsequent death and cardiovascular hospitalization in HFpEF and HFrEF. Measuring serial patient-reported outcome measures in the clinical care of patients with HF can provide an updated assessment of prognosis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094302 (TOPCAT) and NCT00047437 (HF-ACTION).

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Pokharel Y, Khariton Y, Tang Y, et al. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Cardiol. 2017. PMID: 29094152. doi:10.1001/jamacardio.2017.3983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。